Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 159.72M P/E - EPS this Y -31.70% Ern Qtrly Grth -
Income -30.01M Forward P/E -3.76 EPS next Y 11.40% 50D Avg Chg 1.00%
Sales 155k PEG - EPS past 5Y - 200D Avg Chg 12.00%
Dividend N/A Price/Book 2.89 EPS next 5Y - 52W High Chg -21.00%
Recommedations 1.30 Quick Ratio 2.07 Shares Outstanding 18.20M 52W Low Chg 55.00%
Insider Own 33.52% ROA -26.79% Shares Float 11.74M Beta 1.95
Inst Own 13.25% ROE -61.09% Shares Shorted/Prior 1.53M/1.39M Price 8.90
Gross Margin 100.00% Profit Margin - Avg. Volume 61,632 Target Price 19.67
Oper. Margin -29,925.00% Earnings Date May 1 Volume 18,383 Change 4.34%
About INmune Bio Inc.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio Inc. News
04/23/24 INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
04/22/24 INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
04/08/24 INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
04/01/24 INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript
03/31/24 INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
03/29/24 INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements
03/28/24 INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
03/26/24 INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
03/13/24 INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
03/05/24 INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
02/12/24 INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
02/06/24 INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
02/04/24 Insiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the company
01/30/24 INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
01/16/24 ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
01/02/24 INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
12/18/23 INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
11/29/23 INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
11/27/23 INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
11/17/23 Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
INMB Chatroom

User Image CEOBuysDisclosures Posted - 5 hours ago

$INMB CEO purchased 18,028 shares at $8.32 for a total of $149,993. Tesi Raymond Joseph now owns 1,538,726 shares. https://ceo-buys.com

User Image DonCorleone77 Posted - 5 hours ago

$INMB Here is the first page of BTIG's report on INMB from yesterday. $21 PT:

User Image OptionWave1 Posted - 6 hours ago

$INMB think we're gonna start seeing volume consistently over 100k from now on

User Image insiderbuyingselling Posted - 7 hours ago

$INMB new insider buying: 29603 shares. http://insiderbuyingselling.com/?t=INMB

User Image OptionWave1 Posted - 7 hours ago

$INMB 🚀 ignition... breakout

User Image OptionWave1 Posted - 8 hours ago

$INMB thru this 10.5 level we can go

User Image OptionWave1 Posted - 9 hours ago

$INMB shorty has a big decision here... make one more attempt or start to cover... we will find out soon. Strong bidders at this high 9 level.

User Image PaulieS13 Posted - 11 hours ago

$INMB ty

User Image TW_Research Posted - 11 hours ago

$INMB Form 4's are out and it's great to see the strong insider buying on the financing. Wonder what they are seeing?

User Image TW_Research Posted - 13 hours ago

@PaulieS13 Not speculation. It’s determined formulaically by market cap. At these levels $INMB is in. My guess is below $8 it becomes unlikely.

User Image PaulieS13 Posted - 13 hours ago

$INMB Is the Russell inclusion just speculation or has management said something

User Image intratio Posted - 17 hours ago

https://www.intratio.com/stock-forecast/INMB Inmune Bio, Inc. Our mathematical model estimates the price of this stock will shortly go down and has low expectations for the future $INMB

User Image Pjbrady10 Posted - 23 hours ago

$INMB Got quiet fast in here......

User Image OptionWave1 Posted - 1 day ago

$INMB close to breaking out of this 1hr bull flag

User Image OptionWave1 Posted - 1 day ago

@TW_Research $inmb Last years minimum market cap was 159.5m https://www.lseg.com/en/insights/ftse-russell/2023-russell-reconstitution-recap-biggest-takeaways

User Image Fullratio Posted - 1 day ago

$INMB debt is 72% smaller than its equity: https://fullratio.com/stocks/nasdaq-inmb/inmune-bio

User Image Jkre Posted - 1 day ago

$INMB make sure you tell your brokerage that you do not want your shares available for the shorts to borrow. That limits the shares even more for the shorts.

User Image Jkre Posted - 1 day ago

$INMB very surprised this isn't up today with the news on stability.

User Image OptionWave1 Posted - 1 day ago

$INMB @TW_Research Can you confirm that Russell inclusion would likely see 1 to 1.5 million share buy in from funds?

User Image Slinga_Malinga Posted - 1 day ago

$INMB done POs

User Image briefingcom Posted - 1 day ago

$INMB: INmune Bio announces the successful completion of the extended stability validation for XPro continuous storage in solution at 2-8C https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240423080633INMB&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image Horsy10 Posted - 1 day ago

$INMB immune bio inc announces 24 month stability validation of xpro for phase iii readiness and commercial supply chain modeling and development of novel of immunogenicity assay

User Image TW_Research Posted - 1 day ago

$INMB Very positive PR today as it shows the Company is already setting the table for their phase 3 trial. INmune also remains on track for pivotal data later this year. https://twresearchgroup.com/2024/04/inmune-bio-inc-announces-24-month-stability-validation-of-xpro-for-phase-iii-readiness-and-commercial-supply-chain-modeling-development-of-novel-immunogenicity-assay/

User Image MajorBlockbuster Posted - 1 day ago

@MNactuary look at $INMB

User Image OptionWave1 Posted - 1 day ago

$INMB another great press release. They are setting the table, already planning Phase 3! Love the innovation. 1000+ June calls set for the Russell run.

User Image G101SPM Posted - 1 day ago

$INMB $10.36 bid. DAC (dollar average cost) $7.66 last $8.77 (12.19.23). EXIT $18.00 - Legacy Holding LH. NEWS: The 24 and 30-month stability test samples passed all chemistry and potency assays; allowing the Company to make a conservative claim of 24-month stability. The 24-month stability claim is consistent with other pegylated cytokines, such as alpha-interferon, and allows the Company to design a global supply chain using proven and established systems. With this data, the company can benefit from such existing systems that use temperature controlled and monitored shipment of liquid-formulation drugs at 2-8C, which is routine across the pharmaceutical industry. The 24-month stability data confirms that XProTM can mirror these established supply chain strategies.

User Image MajorBlockbuster Posted - 1 day ago

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Comm $INMB https://us15.campaign-archive.com/?e=a9d87dd5fd&u=4a549c7aea3073da1e942d0ce&id=22e2a5ddc3

User Image NeverFolding Posted - 1 day ago

$INMB got the drug supply chain, logistics and immunogenicity test all figured out, ready for Phase 3. P2 on track with prior guidance. Ducks lined in a row. One speed... "Go!"

User Image DonCorleone77 Posted - 1 day ago

$INMB INmune Bio announces 24-month stability validation of XPro INmune Bio announces the successful completion of the extended stability validation for XPro continuous storage in solution at 2-8C. The 24 and 30-month stability test samples passed all chemistry and potency assays; allowing the Company to make a conservative claim of 24-month stability. The 24-month stability claim is consistent with other pegylated cytokines, such as alpha-interferon, and allows the Company to design a global supply chain using proven and established systems. With this data, the company can benefit from such existing systems that use temperature controlled and monitored shipment of liquid-formulation drugs at 2-8C, which is routine across the pharmaceutical industry. The 24-month stability data confirms that XPro can mirror these established supply chain strategies.

User Image Stock_Titan Posted - 1 day ago

$INMB INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay https://www.stocktitan.net/news/INMB/i-nmune-bio-inc-announces-24-month-stability-validation-of-x-pro-for-lqa1o0qcs56t.html

Analyst Ratings
Baird Outperform Jun 1, 23
BTIG Buy May 24, 22
B. Riley Securities Neutral May 24, 22
B. Riley Securities Buy Jan 24, 22
B. Riley Securities Buy Apr 21, 21
HC Wainwright & Co. Buy Nov 9, 20
BTIG Buy Sep 1, 20
HC Wainwright & Co. Buy Jul 15, 20
HC Wainwright & Co. Buy May 15, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Moss David J CFO, Treasurer & Sec.. CFO, Treasurer & Secretary Mar 17 Buy 6.425 2,500 16,062 1,250,151 03/20/23
Tesi Raymond Joseph President and CEO President and CEO May 26 Buy 6.41 6,300 40,383 1,520,698 05/31/22
Moss David J CFO, Treasurer & Sec.. CFO, Treasurer & Secretary May 26 Buy 6.53 10,700 69,871 1,247,651 05/31/22